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Gene expressionThe Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 protein is an essential multifunctional regulator
of gene expression. ORF57 interaction with RNA is necessary for ORF57-mediated posttranscriptional
functions, but little is known about the RNA elements that drive ORF57-RNA speciﬁcity. Here, we investigate
the cis-acting factors on the KSHV PAN RNA that dictate ORF57 binding and activity. We show that ORF57
binds directly to the 5′ end of PAN RNA in KSHV-infected cells. Furthermore, we employ in vitro and cell-based
assays to deﬁne a 30-nucleotide (nt) core ORF57-responsive element (ORE) that is necessary and sufﬁcient for
ORF57 binding and activity. Mutational analysis of the core ORE further suggests that a 9-nt sequence is a
speciﬁc binding site for ORF57. These studies provide insight into ORF57 speciﬁcity determinants and lay a
foundation for future analyses of cellular and viral ORF57 targets.u (N.K. Conrad).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative
agent of Kaposi's sarcoma, primary effusion lymphoma (PEL), and
some cases of multicentric Castleman's disease (Cai et al., 2010;
Dourmishev et al., 2003; Mesri et al., 2010). KSHV is a member of the
gammaherpesvirus family which, like all herpesviruses, is character-
ized by both latent and lytic phases of infection. During latent
infection, the virus expresses only a small subset of its genes that
control functions essential for preserving the viral genome and the
cells harboring them. Such functions include viral genome mainte-
nance, immune evasion, and control of host cell proliferation. No viral
progeny are made during this phase. In contrast, lytic infection
involves a regulated cascade of viral gene expression that leads to the
production of infectious virions. Both latently and lytically expressed
genes have been implicated in KSHV pathogenesis.
The herpesviridae have evolved sophisticated mechanisms to
control viral and host gene expression utilizing both viral and cellular
factors. Because KSHVhas a nuclear dsDNA genome, it is not surprising
that KSHV utilizes host factors for transcription andmRNA processing.
However, the virus encodes its own proteins that regulate gene
expression both transcriptionally and posttranscriptionally (Conrad,
2009; Deng et al., 2007; Glaunsinger and Ganem, 2006; Sinclair, 2003;
Staudt and Dittmer, 2007; Swaminathan, 2005). The 51 kDa ORF57
protein (Mta, KS-SM) is a member of a family of proteins conservedthroughout the herpesviridae and it is essential for KSHV replication
(Boyne and Whitehouse, 2006; Han and Swaminathan, 2006;
Majerciak and Zheng, 2009; Majerciak et al., 2007; Ote et al., 2010;
Sandri-Goldin, 2008; Toth and Stamminger, 2008). While ORF57 has
been implicated in the regulation of KSHV transcription (Kirshner
et al., 2000; Malik et al., 2004a; Palmeri et al., 2007), its post-
transcriptional activities aremore extensively studied. ORF57has been
reported to affect nearly every stage of gene expression including RNA
stability, pre-mRNA splicing, RNA export, and translation (Boyne et al.,
2008, 2010;Majerciak et al., 2008;Malik et al., 2004b;Nekorchuk et al.,
2007; Palmeri et al., 2007; Sahin et al., 2010).
ORF57 binds to RNA in vitro and in vivo (Boyne et al., 2008; Kang
et al., 2011; Majerciak et al., 2006; Nekorchuk et al., 2007; Sahin et al.,
2010), but it is currently unknownwhat dictates the speciﬁcity of ORF57
for its targets. Our recent work showed that ORF57 stabilizes PAN RNA
(nut-1, T1.1), a nuclear non-coding polyadenylated RNA (Sahin et al.,
2010; Sun et al., 1996; Zhong et al., 1996). PANRNA accumulates to very
high levels during lytic infection (Song et al., 2001; Sun et al., 1996)
suggesting an important, yet unknown, function in viral replication.
ORF57 enhances the abundance of PAN RNA in transfected cells
(Kirshner et al., 2000; Nekorchuk et al., 2007; Sahin et al., 2010) and it
is essential for PAN RNA accumulation during viral infection (Han and
Swaminathan, 2006; Majerciak et al., 2007). Moreover, ORF57 binds
directly to PAN RNA in cultured cells and RNA-binding is essential for
ORF57 activity (Sahin et al., 2010). A 300-nucleotide (nt) sequence, the
ORF57-responsive element (ORE), in the 5′-endof PANRNA is necessary
for binding and for ORF57-responsiveness. However, the minimal ORE
has not previously been delineated, nor has it been shown that the ORE
is directly and speciﬁcally bound by ORF57.
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cells and we identify a 30-nt core ORE consisting of a predicted stem-
loop structure. The core ORE was deﬁned based on its activity in three
assays. Speciﬁcally, ORF57 binds the core ORE in an in vitro label transfer
assay, it is sufﬁcient to confer ORF57-responsiveness to an intronless β-
globin reporter, and it is necessary for ORF57 responsiveness of PAN
RNA. We additionally identiﬁed point mutations in the 30-nt core ORE
that abrogate binding in vitro and compromise ORF57 response in cells.
These analyses implicate a 9-nt sequence in an unstructured loop of the
coreOREasapotentialORF57-binding sequence. Recognitionof the core
ORE by ORF57 is likely sequence-speciﬁc rather than structure-based,
because alterations in stems adjacent to the 9 nt sequence had little
effect on ORF57 binding in vitro. Our analyses also reveal that, while the
core ORE is necessary, additional sequences in the full-length ORE are
required for robust ORF57-mediated enhancement of PAN RNA levels.
These data are the ﬁrst to clearly delineate an ORF57-interacting RNA
sequence of a nuclear target of ORF57. In the long term, these data
provide an important foundation to inform future investigations of
ORF57 speciﬁcity and mechanisms.
Results
ORF57 binds to the 5′ end of PAN RNA in lytically reactivated cells
In transiently transfected cells, PAN RNA response to ORF57 is
dictated by a 300-nt ORE at the 5′ end of the transcript (nt 13–312),
which will be referred to as the full-length ORE throughout this
manuscript. Based on these observations, we hypothesized that the 5′
end of PAN RNA contains a high-afﬁnity binding site and that this site
is important for ORF57 binding in infected cells (Sahin et al., 2010).
We employed an ultraviolet (UV) cross-linking approach to examine
whether ORF57 binds to the 5′ end of PAN RNA in KSHV-infected cells
(Conrad, 2008; Sahin et al., 2010; Ule et al., 2005). In this assay,
lytically reactivated cells are exposed to UV light, lysed, and a partial
RNase digestion is performed to cleave the RNA into random
fragments prior to immunoprecipitation of the RNA-protein com-
plexes with ORF57 antibodies. The immunoprecipitated RNA frag-
ments are then analyzed by quantitative reverse transcription PCR
(qRT-PCR) with primers that span four different regions of PAN RNA
(Fig. 1A, boxes labeled A–D). Because UV light solely cross-linksA
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Fig. 1. ORF57 binds the 5′ end of PAN RNA in lytically reactivated cells. (A) Schematic
diagram of PAN RNA with approximate positions of qRT-PCR amplicons shown below.
Primer set A, B, C, and D amplify PAN RNA base pairs 50–124, 293–372, 642–728, and
994–1064, respectively. The numbering system for PAN RNA in this manuscript is
relative to the start site as deﬁned in Zhong et al. (1996). (B) Results from UV cross-
linking immunoprecipitation experiments. The y-axis shows the immunoprecipitation
efﬁciencies relative to that for primer set A (see Materials and methods). The error bars
are standard deviation (n=3).protein-RNA interactions in very close proximity, the immunopreci-
pitated RNA fragments represent those that are directly bound by
ORF57.
Examination of the relative immunoprecipitation efﬁciencies of
each segment of PAN RNA shows a clear 5′ bias (Fig. 1B, black bars).
Because viable cells are exposed to UV light in this procedure,
demonstration of a UV-dependent cross-link reveals that the interac-
tion occurs in living cells. Importantly, we see no immunoprecipitation
of PAN RNA in the no-UV control (white bars), so we conclude that the
interaction with ORF57 exists in lytic phase cells. Additionally, little to
no immunoprecipitation was observed when pre-bleed serum was
used in place of anti-ORF57 antibodies (gray bars).Whilewe observe a
5′ bias, comparison of the test samples to the no-UV and pre-bleed
controls for primer sets B and C show statistically signiﬁcant
immunoprecipitation (pb0.05, Student's t-test). One interpretation
of this observation is that there are multiple binding sites throughout
these regions of PAN RNA. Alternatively, it is possible that the RNAwas
not digested sufﬁciently for resolution of independent fragments. The
values for primer set D at the 3′ end of the transcript do not rise above
statistical signiﬁcance (pN0.1), so our data do not support the
existence of an interaction between the 3′ terminus of PAN RNA and
ORF57. We conclude that ORF57 binds PAN RNA directly during KSHV
lytic infection and that the predominant binding site lies at the 5′ end
of the transcript.
ORF57 binds speciﬁcally and directly to the PAN ORE
To further explore the interaction between ORF57 and the ORE, we
employed an in vitro UV cross-linking, or label transfer, assay (Fig. 2).
In these assays, a radiolabeled RNA substrate is incubated in cell
extract and exposed to UV light to covalently cross-link the proteins
bound to the substrate RNA. After cross-linking, the RNAs are digested
essentially to completion with RNase. However, small cross-linked
RNA fragments (~1–10 nt) are protected from degradation due to the
attached protein. The cross-linked protein-RNA complexes can be
visualized by Phosphorimager analysis of protein gels by virtue of the
radiolabeled RNA. We synthesized uniformly radiolabeled substrates
containing the full-length ORE sequence and a control sequence
lacking the ORE derived from the 3′ end of PAN RNA (Fig. 2A, top). We
incubated these RNAs in whole cell lysate from cells expressing Flag-
tagged ORF57 (Fl-ORF57) or an empty vector control and performed
the label transfer assay. The ORE substrate cross-links to a ~51 kDa
protein in extract containing ORF57 but not in those extracts
transfected with empty vector (lanes 1, 2). The 51 kDa protein is
immunoprecipitated with polyclonal antibodies speciﬁc for ORF57,
conﬁrming the identity of this protein as ORF57 (lanes 3, 4). In
contrast, the control substrate showed no binding to ORF57 in this
assay (lanes 5–8). These experiments demonstrate that ORF57 binds
speciﬁcally and directly to the ORE in whole cell extract and that those
interactions reﬂect the binding patterns observed in infected cells
(Fig. 1).
We further exploited the label transfer assay to deﬁne the
sequences necessary for ORF57 binding. Initially, we divided the full-
length ORE into four non-overlapping 79/80-nt substrates (Fig. 2B, top
and lanes 1–6). The 5′-most of these substrates (nt 1–79) is sufﬁcient
for efﬁcientORF57 cross-linking,while the other three show little to no
ORF57 binding. Next, we examined whether PAN RNA nt 1–79 are
necessary for ORF57 interaction with the ORE, by deleting this
sequence from the full-length ORE (nt 79–315). Surprisingly, this
substrate binds to ORF57 even though its three constituent 79-nt
fragments do not (lane 8 vs lanes 4–6). One possible explanation for
this observation is that a secondORF57 binding site resides near nt 158
or nt 237, the endpoints of the shorter substrates. Therefore, we tested
two overlapping fragments including the natural junctions between
the individual 79-nt substrates (nt 79–237 and 158–315) and found
that both of these fragments bind ORF57 (lanes 11–14). Two models
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Fig. 2. ORF57 binds directly to the ORE in vitro. (A) Label transfer and immunoprecipitation assay. Top, Schematic diagram showing the positions of the full-length ORE or control
substrate in PAN RNA. Bottom, Results from a representative label transfer assay. Extracts from cells expressing or not expressing ﬂag-tagged ORF57 (Fl-ORF57) were incubated with
the indicated substrate as described in theMaterials andMethods. The cross-linked, RNase-treated extracts were then immunoprecipitated using anti-ﬂag antibodies; 10% of input is
shown. The bottom panels show an anti-ﬂag western blot of the same samples demonstrating expression and immunoprecipitation of Fl-ORF57. (B) Label transfer assays with
substrates derived from the ORE region. Top Schematic showing the substrates and their position with respect to the full-length ORE. The bottom panels show the label transfer assay
with extract from cells expressing Fl-ORF57 or not as indicated above each lane. The position of ORF57 is indicated by the arrow.
109E. Sei, N.K. Conrad / Virology 419 (2011) 107–116are consistent with these data. It is possible that the RNA sequences
surrounding nt 158 and 237 contain two independent ORF57 binding
sites. However, based on observations in cultured cells (see below),we
favor the model that the ﬁrst 79 nt of PAN RNA contain a high-afﬁnity
ORF57 binding site, while nt 79–315 contain multiple lower-afﬁnity
binding sites.
PAN RNA nt 1–79 are sufﬁcient to confer ORF57-responsiveness to a
heterologous transcript
Wenext utilized a β-globin reporter assay (Sahin et al., 2010) to test
whether nt 1–79 are sufﬁcient to confer ORF57-responsiveness in cells.
We inserted ORE fragments into the 3′ UTR of a β-globin reporter
construct fromwhich both β-globin introns had been removed (βΔ1,2;
Fig. 3A). Our previous studies showed that co-transfection of ORF57
increases βΔ1,2 mRNA levels in a dose-dependent fashion, even in the
absence of the ORE (Sahin et al., 2010). However, inclusion of the full-length ORE increases the ORF57-speciﬁc response (Fig. 3A, lanes 1–6;
Fig. 3B, black and orange bars). We placed the four 79/80-nt non-
overlapping fragments described in Fig. 2 into the 3′UTR of βΔ1,2 and
determined ORF57-responsiveness by northern blot (lanes 7–18).
Quantiﬁcation of the data shows that the ﬁrst 79 nt of PAN RNA confer
equivalent ORF57-responsiveness to βΔ1,2 as the full-length ORE
(Fig. 3B, purple bars). Because nt 79–315 maintained binding to
ORF57 in label-transfer assays (Fig. 2), we also inserted this fragment
into βΔ1,2 (lanes 19–21). We observe a minimal ORF57 response with
this insert (red bars). The effect is above background only at the highest
concentration of ORF57 tested (compare red to black bars for 0.1 μg and
0.4 μg ORF57 samples). Taken with the in vitro results, these data
support the model that nt 79–315 have low afﬁnity for ORF57 and thus
rely upon greater ORF57 levels to confer ORF57-dependent up-
regulation. Most importantly, these data strongly support the conclu-
sion that nt 1–79 contain a high-afﬁnity ORF57 binding site, which is
sufﬁcient for ORF57-responsiveness in a heterologous context.
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Fig. 3. The ﬁrst 79 nt of PAN RNA are sufﬁcient for ORE activity in a heterologous transcript. (A) Top, Schematic diagram of the intronless β-globin reporter. Different portions of the
ORE were placed into the 3′ UTR (“PAN Insert”) and tested for ORF57-responsiveness by northern blot. A representative northern blot with β-globin is shown below. The β-globin
panels are from the same gel and are shown at the same exposure. The control lanes are probed for a co-transfected loading control. Amounts of co-transfected Fl-ORF57 and the
particular insert are given above each lane. (B) Quantiﬁcation of the northern blot data; error bars are standard deviation (n=3). Each value is relative to the no-insert control with
0.4 μg of ORF57.
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sufﬁcient to confer ORF57-responsiveness
To determine a core sequence that is sufﬁcient for ORF57 binding
in vitro and for its activity in cells, we further dissected PAN RNA nt
1–79. The Mfold RNA secondary structure algorithm (Zuker, 2003)
predicted that PAN RNA contains three stem-loop structures within nt
1–79 (Fig. 4A; SL1, SL2, SL3). We ﬁrst determined whether any of
these loops are necessary for ORF57 binding in cell extract (Fig. 4B).
Deletion of SL1 or SL3 from nt 1–79 have no effect on ORF57 binding
(Fig. 4B; ΔSL1, ΔSL3; lanes 3, 4, 7, 8), while ORF57 cross-linking is
completely lost upon deletion of SL2 (lanes 5, 6). The faint protein
band that co-migrates with ORF57 in ΔSL2 substrate lanes cannot be
ORF57 because it is observed in the no ORF57 extract (lane 5). A
substrate that contains the 40-nt SL2 without SL1 or SL3 efﬁciently
cross-links to ORF57 (lanes 11, 12), demonstrating SL2 is sufﬁcient for
binding in whole cell extract. Further reduction of SL2 reveals that the
cross-linking to ORF57 is driven by sequences in the top of the stem-
loop structure. A 30-nt substrate derived from this portion (SL2-T,
Fig. 4A blue) efﬁciently cross-links ORF57 in vitro (lanes 13, 14), while
the bottom portion (Fig. 4A; SL2-B) does not bind (lanes 15, 16). These
results show that the 30-nt SL2-T sequence is necessary and sufﬁcient
to bind ORF57 in cell extract.
We next tested whether SL2 is sufﬁcient to confer ORF57-
responsiveness in a heterologous context by placing SL2, SL2-T, or
SL2-B into the intronless β-globin reporter construct (Figs. 4C and D).
Consistent with the in vitro binding results, SL2 (yellow bars) and SL2-T
(blue bars) are both sufﬁcient to confer ORF57-responsiveness
comparable to nt 1–79 (purple bars), but SL2-B is not (red bars).
Additionally, deletion of SL2 from fragment 1–79 (1-79ΔSL2, brown
bars) abrogated ORF57-responsiveness. Both SL2-B and 1-79ΔSL2 show
limited, but above background, ORF57-responsiveness at high ORF57
levels (0.4 μg). These data suggest that the SL2-T region is a core ORE
capable of conferring ORF57-binding and response. However, the cis-acting factors responsible for the control of RNA levels by ORF57 are
likely signiﬁcantly more complex than a single short RNA element.
SL2-T is necessary for ORE activity in PAN RNA
The data presented above show that ORF57 binds to the 5′ end of
PAN RNA in lytically reactivated PEL cells and that the SL2-T region is
sufﬁcient for ORE activity and binding. If this element is indeed a core
ORE, removal of SL2-T should decrease PAN RNA levels in the presence
of ORF57. To test this, we generated ORE deletions in a previously
described ORF57-responsive cytomegalovirus immediate early (CMV)
promoter-driven PAN RNA (Sahin et al., 2010) and examined their
effects on PAN RNA accumulation in the presence of ORF57 (Fig. 5A).
We deleted the entire SL2 structure (ΔSL2; nt 23–63), the SL2-T region
(ΔSL2-T; nt 28–57), or the predicted upper loop of SL2-T (Δ34-50). The
17 nt deleted in Δ34-50 bind ORF57 in vitro, but are not sufﬁcient to
confer ORF57-response in the β-globin reporter assay (data not
shown). CMV-Δ1, which lacks the full-length ORE, and CMV-WT are
negative and positive controls, respectively. We co-transfected these
constructs with increasing amounts of ORF57 (0, 30 ng, 100 ng, and
400 ng) and quantiﬁed PAN RNA production by northern blot (Figs. 5B
and C). As previously reported, CMV-Δ1 is completely unresponsive to
ORF57 (purple bars). As predicted, deletion of the SL2, SL2-T, or the
upper loop of SL2 abrogate PAN RNA accumulation in the presence of
ORF57 (brown, yellow, or blue bars, respectively). Thus, SL2, and in
particular the SL2-T portion of the predicted stem loop contains a cis-
acting activity necessary for the full ORF57 responsiveness in PANRNA.
Therefore, based on the three assays employed in this study, we
conclude that the core ORE maps to the 30-nt SL2-T.
In vitro binding and β-globin assays suggest that multiple potential
binding sites are present in the ORE and that, at least in some contexts,
they are sufﬁcient for binding and limited activity.Moreover, deletion of
the core ORE does not have as dramatic of an effect on ORE activity as
deletion of the full-lengthORE. Therefore,we tested a deletion construct
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Fig. 4. A 30 nt stem-loop structure is sufﬁcient for ORE activity and binding. (A) Predicted secondary structure of PAN RNA nt 1–79. The three stem loops are labeled SL1, SL2, SL3 and
the SL2 “top” (SL2-T) and “bottom” (SL2-B) portions are shown in ovals shaded with blue and red, respectively. (B) Label transfer assay with substrates that delete each of the stem
loops (lanes 1–8) in the context of the nt 1–79 fragment. Lanes 11–16 show label transfer with SL2, SL2-T, or SL2-B alone. Cross-linking of each substrate is shownwith extract either
containing or lacking Fl-ORF57 as indicated. (C) Each of the indicated fragments was inserted into the intronless β-globin construct and examined for ORF57 response by northern
blot as described in Fig. 3. The dashed lines represent positions where lanes were removed for presentation; the panels displayed are from the same blot at the same exposure.
(D) Quantiﬁcation of the northern blot results was performed as in Fig. 3 (n=3).
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afﬁnity binding sites for ORF57 (Fig. 2). In this case, we observe a similar
lack of response to ORF57 as we do for ΔSL2 (red bars). One
interpretation of this result is that the weak secondary binding sites
observed in the in vitro binding experiments are necessary for full ORE
activity in the context of PAN RNA. Thus, both the core ORE and
secondary sites arenecessary for fullORF57-responsiveness inPANRNA.
Alternatively, the core OREmay be sufﬁcient in PAN RNA, however, the
ORF57 binding site is masked by alterations in RNA secondary structure
introduced by the deletions.
Point mutations in the core ORE abrogate ORF57 binding and activity
To examine activity of the core ORE at the nucleotide level, we
generated a series of six point mutants that alter the 11-nt loop or the
short stem of SL2-T (Fig. 6A). Label transfer assays were employed to
test the ability of ORF57 to cross-link each of the mutant substrates(Fig. 6B). Mutations in the ﬁrst two nucleotides of the 11-nt loop have
no effect on ORF57 binding (CU→AA37–38 lanes 3, 4). In contrast,
ORF57 does not bind to any of the other three mutants tested in the
SL2-T loop (lanes 5–8, 11, 12). We also made mutations that disrupt
the base pairing in the three nt stem structure immediately below the
SL2-T loop. Neither of these mutations affect ORF57 binding (lanes
13–16), demonstrating that this structure is not necessary for ORF57
binding in vitro. We additionally generated a substrate containing
mutations that restore the stem by combining CAC→GUG34–36 with
GUG→CAC48–50. As predicted from the lack of effect of the individual
triple point mutants, these compensatory mutations had no effect on
ORF57 binding in vitro (data not shown). Together, these data suggest
that the sequences in nt 40–47 comprise a sequence-speciﬁc binding
site for ORF57 and that the secondary structure contributes little to
binding in vitro.
One caveat to in vitroUV cross-linking is that, while all bases can be
cross-linked, uridine bases cross-link with much greater efﬁciency
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inhibit cross-linking, but not binding to ORF57. This is especially true
for the UUU→AAA45–47 mutant which replaces three uridine residues
in the putative ORF57 binding site. As a complementary approach, we
performed RNA immunoprecipitation from extract in the absence of
cross-linking (Fig. 6C). Labeled SL2-T or UUU→AAA45–47 substrate
was incubated in extract containing or lacking Fl-ORF57 and
subsequently immunoprecipitated using anti-ﬂag antibodies. Consis-
tent with the UV cross-linking results, the immunoprecipitation
efﬁciency of SL2-T is signiﬁcantly more robust (~10-fold) than the
UUU→AAA45–47 substrate. Thus, the UUU→AAA45–47 mutation
abrogates both cross-linking and binding of ORF57 in vitro, supporting
the conclusion that nt 45–47 are part of a sequence-speciﬁc binding
site for ORF57.
We next introduced the mutations that abrogate binding in vitro
into the PAN RNA expression constructs and examined their effects on
PAN RNA accumulation in the presence of ORF57 (Figs. 6D and E).
While the mutated constructs retain signiﬁcant ORF57-responsive-ness (Fig. 6D), accumulation of PAN RNA is reduced by 2-fold in two of
the mutants (UG→AA40–41, GAU→AAA42–44). The two-fold effect is
observed both at 100 ng and 400 ng of ORF57 and is highly
statistically signiﬁcant (pb0.005), so we conclude that these speciﬁc
nucleotides are central to ORF57 activity on PAN RNA. The third
mutation tested, UUU→AAA45–47, reduces PAN RNA levels by a small
(30%), but statistically signiﬁcant (pb0.005), quantity when co-
transfected with 100 ng ORF57. Upon transfection of four times as
much ORF57, the difference still exists, but it is of questionable
statistical signiﬁcance (p=0.057). Taken together, these data suggest
that the nucleotide sequence AUGGAUUUU contributes signiﬁcantly
to the binding of ORF57 to PAN RNA, but also demonstrate that other
binding sites contribute to the ORF57 response.
Discussion
The ORF57 protein is an essential KSHV factor withmultiple roles in
viral gene expression (Boyne and Whitehouse, 2006; Conrad, 2009;
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Fig. 6. Point mutations in the loop portion of SL2-T abrogate ORF57 binding and response. (A) Schematic diagram of triple and double point mutations generated in SL2-T. The
mutations introduced are shown in red adjacent to the name of the mutant. (B) Label transfer assays with mutant substrates. The mutant substrates were generated in the context of
the SL2-T sequence, which is used as a positive control (lanes 1, 2, 9, 10). Presence of Fl-ORF57 in the extract is indicated above each lane and the position of ORF57 is given by the
arrow. (C) RNA immunoprecipitation of SL2-T and UUU→AAA45–47 substrates. Five percent of input and 100% of pellets are shown at the same exposure from the same gel of an
immunoprecipitation experiment with anti-ﬂag agarose beads. The presence or absence of Fl-ORF57 is indicated above each lane as is the substrate. (D) Representative northern blot
data analyzing the effects of the indicated mutations on ORF57 responsiveness probed for PAN RNA or a co-transfected loading control. The PAN RNA panels are from the same
gel and are from the same exposure. (E) Quantiﬁcation of northern blots. Values are relative to the CMV-WT at 100 ng transfection. The error bars are standard deviation (n=3). The
p-values are derived from a two-tailed unpaired Student's t-test comparing each sample to the WT.
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role in transcription, most of its proposed activities involve posttran-
scriptional regulation of RNA metabolism and its RNA-binding proper-
ties are important for these functions. However, themechanismsORF57
uses to recognize its ligand RNAs are unknown. Here, we delineate a
core ORF57-responsive element in PAN RNA, a known ORF57 target in
both cultured and infected cells (Han and Swaminathan, 2006; Kirshner
et al., 2000; Majerciak et al., 2007; Nekorchuk et al., 2007; Sahin et al.,
2010). Conservatively, we deﬁne the core ORE to be a 30-nt sequence,
SL2-T, because it ﬁts all three criteria tested in the presentwork. That is,
SL2-T 1) binds to ORF57 in vitro, 2) enhances intronless β-globin RNA
levels in the presence of ORF57, and 3) is necessary for ORF57-
responsiveness of PAN RNA.Most likely, the core activity is contained in
an even smaller region. Speciﬁcally, thenucleotidesAUGGAUUUU in the
unstructured loop at the top of the coreOREare essential for binding and
for full ORF57-responsiveness in PAN RNA. Thus, these nine nucleotides
may constitute an ORF57 RNA binding motif.
ORF57 post-transcriptionally enhances the expression of many viral
genes as well as various reporter constructs, so it may seem that its
binding to RNA is relatively nonspeciﬁc. Indeed, in our β-globin assays
(Figs. 3 and 4) there is a consistent background of ~4–5-fold
enhancement by ORF57 in the absence of any ORE. This relatively
non-speciﬁc effect may be important for the biology of ORF57. In
mammalian cells, the stages of nuclear pre-mRNA processing are tightly
coupled, and abrogation of one activity often affects other processing
steps (LeHir et al., 2003; Pandit et al., 2008; Reed, 2003; Vinciguerra andStutz, 2004). Pre-mRNA splicing is central to this coupling, but most
KSHV transcripts lack introns (Zheng, 2003). As a result, KSHVgenes are
missing an important component of efﬁcient expression. One ascribed
function of ORF57 is to enhance the expression of intron-lacking viral
mRNAs. As such, it seems likely that ORF57 would evolve a relatively
promiscuous binding speciﬁcity to enable it to bind the large pool of
intronless viral mRNAs expressed during lytic phase. Peculiarities of
individual viral transcripts may require more robust binding by ORF57
to yield a higher activity. For example, the nuclear accumulation of PAN
RNA appears to require a stable complex with ORF57 to protect it from
nuclear decay enzymes. Perhaps in these cases, transcripts evolved cis-
acting OREs like the one described here.
While this work was in preparation, Zheng and colleagues
published a different ORF57-responsive element derived from the
viral interleukin-6 (vIL-6) mRNA (Kang et al., 2011). The vIL-6 MRE
(Mta-responsive element) overlapped with a miRNA binding site and
the authors proposed that binding of ORF57 antagonized the down-
regulatory effects of themiRNA.While thismechanism is unlikely to be
responsible for ORF57-dependent stabilization of the nuclear PAN
RNA, binding of ORF57 to the vIL-6 MRE or to the PAN ORE is essential
for its regulatory function. Comparison of the core PAN ORE with the
vIL-6 MRE reveals little overall sequence homology. However, there
are two interesting similarities. Consistent with the idea that high-
afﬁnity ORF57 binding is driven by sequence rather than structure,
both elements are predicted to fold into stem-loops, but neither shows
particularly strong secondary structures. Even more compelling, the
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tetranucleotide GGAU. This element is necessary for ORE activity
because mutation of this motif (UG→AA40–41, GAU→AAA42–44)
abrogates binding in vitro and ORF57-responsiveness in cells. Thus,
these data suggest that the GGAU motif may provide sequence
speciﬁcity for ORF57 binding that is utilized in multiple transcripts.
Interestingly, the herpesvirus saimiri ORF57 protein has been reported
to preferentially bind a purine-rich GGAGRG element (Colgan et al.,
2009), so there may be at least loose conservation of binding-site
speciﬁcity with respect to the GGA trinucleotide. Identiﬁcation and
detailed examination of additional ORF57-responsive elements is
necessary to test whether this sequence is a general feature of ORF57
regulated RNAs.
In the same study that identiﬁed the vIL-6 MRE (Kang et al., 2011),
a nonbiased approach was taken to clone viral RNA fragments that
interact with ORF57. Consistent with our results, they found that PAN
RNA interacted with ORF57; 16 out of 91 PAN RNA clones (18%)
overlapped the SL2-T core ORE sequence. Surprisingly, other clones
spanned nearly every region of PAN RNA with close to 50%
overlapping the ENE, a cis-acting stability element in PAN RNA
(Conrad and Steitz, 2005; Conrad et al., 2006, 2007). No validation of
the cloned PAN RNA fragments for their ability to confer ORF57-
responsiveness was performed in that study, but our data clearly
show that ORF57 binding and response is conferred by sequences
residing at the 5′ end of PAN RNA. In fact, deletion of the ENE actually
increases ORF57-responsiveness, presumably due to the fact that
ORF57's stabilization effects are greater on an inherently less stable
transcript (Sahin et al., 2010). Moreover, our in vivo and in vitro UV
cross-linking results do not support a direct interaction between
ORF57 and the 3′ end of PAN RNA (Figs. 1 and 2).
Our data are consistent, however, with the general model that the
core ORE is not the only binding site in PAN RNA for ORF57. Sequences
contained in nt 79–315 bind PAN RNA in vitro and deletion or
mutation of the core ORE is not sufﬁcient to completely abrogate
ORF57-responsiveness (Figs. 5 and 6). In contrast, when the full-
length ORE is deleted, virtually no ORF57 response is observed. We
speculate that the core ORE efﬁciently recruits ORF57, which has been
shown to be in a homomultimer complex of unknown number
(Nekorchuk et al., 2007). Once one ORF57 molecule is bound to the
ORE, the RNA binding domain(s) on the unbound ORF57 molecule(s)
are present in a high local concentration driving binding to weaker
sites in adjacent sequences. Similar cooperative models have been
proposed for other RNA-binding proteins like hnRNP A1 and the HIV
REV protein (Daugherty et al., 2008; Zhu et al., 2001). The presence of
high ORF57 levels and/or multiple weak ORF57-binding sites can
drive this interaction in the absence of a high-afﬁnity ORE leading to
the observed ORF57 promiscuity.
The steady-state analyses of PAN RNA and β-globin used in this
study monitored the accumulation of transcript as a measurement of
ORF57 activity. These approaches are confounded by the presence of
an uncharacterized enhancer of PAN RNA expression that overlaps the
full-length ORE (Conrad and Steitz, 2005; Sahin et al., 2010). When
driven by the PAN RNA promoter, deletion of the full-length ORE
decreases PAN RNA levels by ~5-fold in the absence of ORF57. Use of
the CMV promoter decreases the magnitude of the effect of this
enhancer, but some up-regulation of RNA levels by this element is still
observed. Close examination of the no ORF57 controls in this study
suggests a subtle trend of increased RNA accumulation in the presence
of the core ORE in the absence of ORF57 (Figs. 3–6). To be sure, careful
quantiﬁcation of these data rarely yields a statistically signiﬁcant effect
(data not shown), so it is difﬁcult to interpret the relevance of the
trend.One formal possibility is that the coreOREdoesnot driveORF57-
response directly, but rather it is an element that has a function in gene
expression that lies upstream of ORF57 activity. However, this idea
seems unlikely based on our in vitro binding and β-globin reporter
assays. We favor the idea that the element may bind to cellular factorsthat act in concert with ORF57 to promote gene expression. In the
absence of ORF57, the activity of the cellular factor isminimized, but in
its presence the effect is enhanced. Consistent with this idea, in vitro
binding of baculovirus-expressed ORF57 is enhanced by the presence
of cellular extract (Majerciak et al., 2006). Further experimentation is
required to unravel the complex molecular mechanisms of these
primary and secondary ORF57-responsive elements in PAN RNA.
ORF57 is a multifunctional regulator of gene expression that is
essential for KSHV replication. In order to take a meaningful global
approach to examine ORF57 targets, we must ﬁrst employ reduction-
ist techniques to deﬁne the requirements for ORF57-RNA interactions.
Here we have identiﬁed a core element from a natural ORF57 target
that is sufﬁcient for ORF57 binding and response. These data provide a
foundation to compare ORF57-responsive elements from novel viral
and cellular targets as they are uncovered.
Materials and methods
Plasmids
The βΔ1,2, CMV-WT, CMV-Δ1, PANΔ79, PAN-WT and pcFl-ORF57II
expression constructs were described previously (Conrad and Steitz,
2005; Conrad et al., 2006, 2007; Sahin et al., 2010). The PAN RNA
inserts for the β-globin reporter assay were generated by PCR
ampliﬁcation of the corresponding sequences using the primers listed
in the Supplementary Content with PAN-WT as a template. The
PANΔ79-ΔSL2 construct (see below) was used as a PCR template for
the ΔSL2 insert. The resulting PCR products were digested with NotI
and XhoI and inserted into the βΔ1,2 plasmid cut with the same
restriction enzymes. Smaller inserts were created by annealing DNA
oligonucleotides with the appropriate NotI and XhoI overhangs. In
this case, each oligonucleotide was 5′ phosphorylated with T4
polynucleotide kinase prior to annealing using standard procedures.
Prior tomaking the CMV-driven PANRNA expression constructs, the
deletions in the ORE were ﬁrst introduced into PANΔ79 by SOEing PCR
(Horton, 1995). The primer sets used are listed in the Supplementary
Content. Products were digested with PﬂMI and NcoI and inserted into
the same sites on PANΔ79. NcoI was substituted by AfeI where
appropriate. The CMV-driven PAN RNA deletion plasmids were
constructed by PCR ampliﬁcation of PAN RNA sequences from these
PANΔ79 derivatives using primers NC872 (5′ agtcctAAGCTTactggg-
actgcccagtcacc 3′) and NC10 (5′ gggggcccgtcacatttagggcaaagtgg 3′). The
PCR products were digested with HindIII and XbaI and ligated into
the CMV-WT plasmid cut with the same enzymes. Point mutants in
CMV-WTwere createdusing the sameSOEingapproach and theprimers
are listed in the supplemental content. The sequence of all PCR-
generated inserts was veriﬁed.
Cell culture and transfection
TREx BCBL1-Rta cells (Nakamura et al., 2003) were carried in
RPMI-1640 media (Sigma) supplemented with 10% tetracycline-free
FBS (Clontech), penicillin-streptomycin (Sigma), 2 mM L-glutamate,
and 100 μg/ml hygromycin (Sigma). HEK293 cells were grown as
previously described in (Sahin et al., 2010).
HEK293 cells were transfected using TransIT-293 (Mirus).β-globin
reporter constructs were transfected in 12-well tissue culture plates
with a total of 0.8 μg plasmid DNA. A typical transfection contained
0.4 μg of pcFl-ORF57II plus pcDNA3, 0.1 μg of a control plasmid (mgU2-
19/30) (Sahin et al., 2010), and 0.3 μg of the β-globin reporter. For the
CMV-PAN derivatives, β-globin reporter DNA was substituted by
0.3 μg of a PAN RNA expression construct. Total RNA was harvested
18–24 h after transfection using TRI Reagent (Molecular Research
Center) and analyzed by northern blotting using standard procedures
(Church and Gilbert, 1984; Conrad and Steitz, 2005). Riboprobes
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used to normalize RNA recovery and loading.
Antibodies
ORF57 antibodies were made in rabbits (Cocalico Biologicals)
using a mixture of two bacterially expressed ORF57 polypeptide
sequences, fm9 (amino acids 1–153) and fm7 (amino acids 171–455).
Due to propensity of these proteins to precipitate, they were kept
under denaturing conditions (0.5% SDS or 8 M urea) for the entire
preparation. ORF57 antibodies were afﬁnity puriﬁed from rabbit
serum using the Microlink Peptide Coupling kit (Pierce) as per the
manufacturer's instructions. The afﬁnity puriﬁed antibody recognized
a single 51-kDa protein on western blots of lysate from infected or
transfected ORF57-expressing cells, but not from that of cells that did
not express ORF57 (data not shown). Pre-bleed antibodies were
puriﬁed with Protein A beads (Pierce) using standard procedures.
UV cross-linking and immunoprecipitation
TREx BCBL1-Rta cells at 5×105cells/ml were reactivated by
treatmentwith1 μg/mldoxycycline (Fisher) and3 mMsodiumbutyrate
(Sigma) for 18–20 h. A total of 1×107 cells/condition were washed in
10 ml of phosphate-buffered saline (PBS; Sigma), centrifuged at 700×g
for 3 minat4 °Cand resuspended in3 mlof PBS. Thecell suspensionwas
transferred to a 10 cm cell culture dish and irradiated on ice at
250 mJ/cm2 ~2–3 cm from the UV source (Spectroline XL-1500,
254 nm). After cross-linking, 7 ml of PBS were added to the dish. Cells
were transferred to 15 ml conical tubes, and centrifuged at 700×g for
3 min at 4 °C. Cell pelletswere resuspended in 1 ml PBS and centrifuged
at 2400×g for 1 min at 4 °C. PBS was removed and the pellets were
frozen at −80 °C (Conrad, 2008). Cell lysis and immunoprecipitation
were performed essentially as previously described (Conrad, 2008)
except addition of poly(U) RNA was omitted and the QIAshredder step
was substituted by digestion with 30 μl of RQ1 DNase (Promega) for
15 min at 25 °C. Subsequently, 10 μl of 1 μg/ml RNase A (Sigma) was
added and incubated at 25 °C for 10 min (Ule et al., 2005). For the
immunoprecipitation, approximately 8 μg of antibody (pre-bleed or
αORF57)were added to the extracts,whichwere then nutated for 1 h at
4 °C. The extracts were then added to 20 μl of protein-A agarose beads
(Pierce) and nutated for an additional hour at 4 °C. Washing of bound
antibody complexes, elution and RNA recovery were performed exactly
as described (Conrad, 2008).
To analyze the RNAs recovered from the UV cross-linking protocol,
the input and pellet samples were DNase treated for 1 h at 37 °C in a
20 μl reaction containing 2 μl of RQ1 DNase, 20 units of RNasin Plus
(Promega), and DNase Buffer (40 mMTris pH 8.0, 10 mMMgSO4, 1 mM
CaCl2). The reaction volume was brought up to 200 μl in G-50 Buffer
(20 mMTris pH 7.5, 0.25% SDS, 0.3 M sodium acetate, 2 mM EDTA) and
then extracted with an equal volume of phenol:chloroform:isoamyl
alcohol (25:24:1; PCA). An aliquot of the resulting RNAs (~1/7) was
ethanol precipitated with 15 μg of glycoblue (Ambion). Reverse
transcription reaction was performed using SuperScript™ II RT
(Invitrogen) and random hexamers (Sigma) as per the manufacturer's
protocol. No-RT controls were performed in parallel for each sample.
Inputs and pellets were diluted 40-fold, 2 μl of which was used as
template for real-time PCR as described (Sahin et al., 2010). Real-time
primer sets were: A, NC702 (5′ GCTCGCTGCTTGCCTTCTT 3′) and NC703
(5′ CCAAAAGCGACGCAATCAA 3′); B, NC704 (5′ CTTGCGGGTTATTGCA-
TTGG 3′) and NC705 (5′ GACACGTTAAGTATCCTCGCATATCA 3′);
C, NC706 (5′ TTTTCCAGTGTAAGCAAGTCGATTT 3′) and NC707
(5′ TGTTCTTACACGACTTTGAAACTTCTG 3′); D, NC708 (5′ TTAACGT-
GCCTAGAGCTCAAATTAAAC 3′) and NC709 (5′ TTGACCTTTATTTATG-
TTGTAAGTTGCATTA3′). Efﬁciency of theA, B, C andDampliﬁcationswas
determined to be 92%, 91%, 82% and 83%, respectively (Pfafﬂ, 2001).
Relative quantities (RQ) of Inputs and Pellets were determined based ontheir ampliﬁcation efﬁciency and Ct value. The RQ value for the no-RT
controls was subtracted from the plus RT samples. Immunoprecipitation
efﬁciency was determined by calculating the pellet/input ratio of the
background corrected values. To compare between experiments, these
valueswere thennormalized to the“+UV/αORF57” ratio for primer setA.
Label transfer experiments
DNA templates for in vitro transcription of each substrate were
generated by PCR ampliﬁcation using primers containing the T7
promoter sequence (Supplemental Content). In the case of ΔSL2,
template was ampliﬁed from PANΔ79-ΔSL2, while all others utilized
PAN-WT as a template. The smallest T7-DNA templates were made by
annealing oligonucleotides. Each oligonucleotide pair was heated at
90 °C for 3 min in annealing buffer [10 mM Tris pH 7.5, 150 mM NaCl,
25 mM EDTA, 2.5 μM each oligonucleotide] and then slowly equili-
brated to room temperature. Body labeled RNA fragments were
generated in a 20 μl reaction containing 50 units of T7 RNA
polymerase, 5 μl α-32P-UTP (800 Ci/mmol, 0.010 mCi/μl), 20U RNasin
Plus and transcription buffer (40 mM Tris pH7.5, 6 mM MgCl2, 4 mM
spermidine, 50 μM UTP, 1 mM ATP, 1 mM CTP, 1 mM GTP, 10 mM
DTT). Transcription reaction was run through an illustra MicroSpin™
G-25 column (GE), the RNA was ethanol precipitated with 1 M
ammoniumacetate and glycoblue, and then separated on a urea-PAGE.
Full length RNAs were excised from the gel and eluted in G-50 buffer
overnight at room temperature. Eluted fractions were extracted with
PCA, ethanol precipitated, and resuspended in water. RNA yield was
approximated by scintillation (Cerenkov) counting.
Whole cell extracts were made by transfecting a 10 cm dish with
10 μg of either pcDNA3 or pcFl-ORF57II. After 48 h, cellswere harvested,
washedwith PBS, and the cell pelletswere collected by centrifugation at
2400×g for 1 min at 4 °C. The pelletswere subsequently resuspended in
300 μl of RSB100T-Plus [10 mM Tris pH 7.5, 2.5 mM MgCl2, 100 mM
NaCl, 0.5% TritonX100, 1 mM phenylmethanesulphonylﬂuoride (PMSF,
Sigma), protease inhibitors (cocktail V, Calbiochem)], sonicated three
times for 10 s at 30% amplitude (SONICS Vibra-cell™ VCX130 with a
6 mmprobe), and then centrifuged at 16,000×g for 10 min at 4 °C. After
adding glycerol to 10%, the supernatants were stored at−80 °C.
The binding reactions for label transfer assays were performed in a
40 μl reaction volume including 10 μl of whole cell extract, 10 μl
RSB100T (10 mM Tris pH 7.5, 2.5 mM MgCl2, 100 mM NaCl, 0.5%
Triton X-100), substrate (~15 nM), 500 μM MgCl2, 80 mM KCl, 1 mM
ATP, 20 mM creatine phosphate, and 0.3 mg/ml Torula yeast RNA
(Sigma). In some cases 20 μl of extract was used, however, higher
amounts of extract did not affect the ORF57 signal strength. Binding
was allowed to reach equilibrium by incubating at 30 °C for 15 min.
The protein-RNA complexes were then cross-linked on ice at
860 mJ/cm2 in a Spectroline XL-1500 (254 nm). Samples were then
treated with RNase A at 0.25 mg/ml for 30 min at 25 °C. For
immunoprecipitation, 80 μl of RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) were added along with ~4.5 μg of afﬁnity puriﬁed ORF57
antibody and the extract was nutated for 1 h at 4 °C. This mixture was
then transferred to 15 μl of protein-A agarose beads and nutated for an
additional hour at 4 °C. Beads were washed a total of ﬁve times in 1 ml
of RIPA buffer. Proteins were eluted by boiling in SDS gel loading buffer.
The samples were separated on a 10% SDS-PAGE, dried, and exposed on
a Phosphorimager screen.
RNA immunoprecipitation
Binding reactions for RNA immunoprecipitation experiments were
performed as described for the label transfer experiments, except cpm
were equilibrated (6×106 cpm), rather than molarity. After binding,
the volume was increased to 200 μl with RSB100T and the samples
were nutated at 4 °C for 1 h with 15 μl of anti-ﬂag M2 afﬁnity beads
116 E. Sei, N.K. Conrad / Virology 419 (2011) 107–116(Sigma) pre-blocked with yeast RNA. Beads were washed a total of
ﬁve times in 750 μl of RSB100T supplemented with 500 μM MgCl2,
80 mM KCl, and 15 U of RNasin Plus. Proteins from both inputs and
pellets were digested in 200 l of 4 mg/ml proteinase K, 100 mM Tris
pH 7.5, 50 mM NaCl, and 10 mM EDTA for 1 h at 37 °C. Finally, the
samples were extracted in an equal volume of PCA, ethanol
precipitated, and analyzed by urea-PAGE.
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